Drug Profile

Levodropropizine controlled release - Hyundai Pharmaceutical

Alternative Names: HOB-048; Levotuss CR

Latest Information Update: 14 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hyundai Pharmaceutical
Class Antitussives; Small molecules
Mechanism of Action Neuropeptide modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Cough

Most Recent Events

14 Oct 2021 Discontinued - Phase-III for Cough in South Korea (PO) (Hyundai Pharmaceuticals pipeline, October 2021)
01 Oct 2018 Hyundai Pharm completes a phase III trial in Cough in South Korea (PO, Tablet, Syrup) (NCT03489837)
23 Jan 2018 Levodropropizine controlled release is still in phase III trials for Cough in South Korea (Hyundai Pharmaceuticals pipeline, January 2018)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com